Autonomix Medical, Inc. AMIX

Autonomix Medical announced European Patent No. EP 4 233 700 B1, titled 'Systems for Assessing Neural Activity in an Eye,' expanding its international IP portfolio and protection for autonomic nervous system assessment and precision neuromodulation. The patent covers ocular monitoring methods to evaluate physiologic responses for patient assessment, treatment guidance and procedural feedback across autonomic disorders and neuromodulation applications. CEO Brad Hauser says the grant strengthens the company's global footprint and complements existing patents on neural sensing, mapping and transvascular neuromodulation. The release notes a platform featuring catheter-based microchip sensing arrays that may enable transvascular diagnosis and treatment of peripheral nervous system diseases, with initial focus on pain management and trials for pancreatic cancer pain. The technology is investigational and not cleared in the U.S. for marketing. Forward-looking statements caution about risks and SEC filings. Strengthens IP protection in Europe for autonomic nervous system assessment, potentially expanding future opportunities.

Autonomix Medical secured a new U.S. patent for feedback-guided precision neuromodulation and targeted therapy delivery, expanding its intellectual property portfolio. Patent strengthens IP protection for core technology but does not signal immediate commercial or financial shifts.

Autonomix Medical, Inc. entered into a $4.9 million warrant inducement priced at a premium to market under Nasdaq rules. Warrant inducement supplies $4.9 million in capital at premium pricing and bolsters near-term liquidity for operations.

Autonomix Medical completed its GLP preclinical study, advancing toward FDA submission. GLP study completion marks regulatory progress that can accelerate product approval and commercial trajectory.

Autonomix Medical receives U.S. patent for expansion of its precision neuromodulation platform. Patent grant secures core neuromodulation technology and strengthens competitive positioning.

Autonomix Medical secures broad new U.S. patent expanding its precision neuromodulation platform to support nerve sensing, mapping and targeted therapy. Broad patent grant directly strengthens core IP and technology development for neuromodulation applications.

Autonomix Medical demonstrated renal nerve sensing and neural activity change in a preclinical study. Preclinical proof of renal nerve technology supports pipeline progress for Autonomix but remains early-stage.

Autonomix Medical secures new U.S. patent strengthening its next-generation precision neuromodulation platform. New patent strengthens core neuromodulation technology and competitive positioning.

Autonomix Medical granted U.S. patent for overactive bladder diagnosis and treatment platform. Patent grant secures core IP for key platform potentially shifting competitive positioning and trajectory.

Autonomix Medical enters $2.6 million warrant inducement priced at-the-market under Nasdaq rules. Warrant inducement supplies $2.6 million cash to support operations while risking share dilution.

Autonomix Medical receives new neural sensing patent grant strengthening its global intellectual property position. Patent grant improves IP holdings but remains incremental without immediate revenue or operational shifts.

Autonomix Medical launches standalone neural sensing program backed by evidence of real-time renal nerve activity change. Standalone neural sensing program with renal nerve activity evidence advances core technology and clinical prospects.

Autonomix Medical highlighted clinical data presented at the Society of Surgical Oncology Annual Meeting during a Virtual Investor "What This Means" segment featuring City of Hope Chief of Medicine. Clinical data presentation at major oncology meeting raises visibility and credibility for Autonomix Medical's core technology.

Autonomix Medical, Inc. receives U.S. patent for transvascular monitoring and treatment systems with real-time procedural validation. Patent strengthens core IP protection and supports future product positioning without immediate revenue effects.

Autonomix Medical announces abstract acceptances at EuroPCR 2026 presenting long-term data on pancreatic cancer pain mitigation. Conference abstract acceptances offer scientific validation and visibility that can moderately lift investor sentiment and support future funding or partnerships.

Autonomix Medical, Inc. (AMIX) announces abstract acceptance at Digestive Disease Week 2026 for long-term data on its technology mitigating pain in pancreatic cancer patients. Abstract acceptance for long-term pancreatic cancer pain data at a major conference signals clinical progress, likely boosting investor sentiment without immediate transformative effects.

Autonomix Medical, Inc. (AMIX) will present long-term data on its pain mitigation technology for pancreatic cancer at the ECIO 2026 conference. Presentation of long-term clinical data at a major oncology conference validates progress in AMIX's lead pain mitigation program for pancreatic cancer, likely influencing investor sentiment moderately.

Autonomix Medical, Inc. (AMIX) selected for featured abstract and podium presentation at SIR 2026 on long-term pain mitigation in pancreatic cancer patients. Featured presentation of long-term clinical data at SIR 2026 validates technology efficacy, likely driving significant investor interest and advancing competitive positioning.

Autonomix Medical, Inc. (AMIX) selected as top abstract at CRT 2026 for podium presentation on clinical feasibility and outcomes of novel transvascular peripheral RF nerve neurolysis technique. Top abstract and podium selection at major conference validates novel neurolysis technology, likely boosting credibility, partnerships, and investor sentiment.

Autonomix Medical, Inc. (AMIX) selected for podium presentation at SSO 2026 Annual Meeting to share new long-term data on pain mitigation technology for pancreatic cancer patients. Podium presentation of new long-term clinical data at a leading surgical oncology conference validates technology and likely enhances AMIX's market position and investor sentiment.

Autonomix Medical, Inc. (AMIX) is set to present its final analysis on pain mitigation in pancreatic cancer at the SIO 2026 Annual Scientific Meeting. This presentation is anticipated to highlight significant advancements in treatment approaches for managing pain associated with pancreatic cancer, potentially influencing future research and clinical practices in this area. The presentation could lead to significant advancements in treatment approaches, impacting the company's strategic positioning and investor sentiment.

Autonomix Medical, Inc. (AMIX) presented compelling clinical data at the 2026 ASCO Gastrointestinal Cancers Symposium, demonstrating rapid and durable pain relief across all disease stages of pancreatic cancer. The point-of-care study highlights the potential effectiveness of AMIX's treatment, which could significantly impact patient care and outcomes in this challenging area of oncology. The presentation of significant clinical data indicating effective pain relief in pancreatic cancer could lead to major strategic advancements and enhance investor sentiment.

Autonomix Medical, Inc. (AMIX) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This surge in activity may reflect broader market trends or specific developments within the company that are attracting attention from traders and analysts alike. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential interest in the company's future performance.

Autonomix Medical, Inc. has been granted a European patent for its innovative platform technology that enables precision nerve-targeted therapies in cardiology. This advancement is expected to enhance treatment options and improve patient outcomes in cardiovascular care, positioning the company favorably in the medical technology sector. The granted patent represents a significant strategic advancement that could enhance product offerings and market positioning.

Autonomix Medical, Inc. (AMIX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Autonomix Medical, Inc. (NASDAQ: AMIX) has announced the expansion of its intellectual property portfolio and a multi-indication platform strategy during a recent Virtual Investor CEO Connect segment. The company is focusing on enhancing its technological capabilities and broadening its applications in the medical field, which could position it favorably in the competitive landscape. The expansion of the IP portfolio and multi-indication strategy is likely to significantly impact the company's future performance and market positioning.

Autonomix Medical, Inc. announced that an abstract has been selected for a poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. This recognition highlights the company's ongoing research and contributions to the field of oncology, particularly in gastrointestinal cancers. The selection for presentation at a prominent symposium indicates moderate recognition and potential influence on the company's reputation and future research opportunities.

Autonomix Medical, Inc. (NASDAQ: AMIX) has released the latest segment of its CEO Corner, emphasizing the company's ongoing execution and strategic growth initiatives. The segment highlights key developments and future plans aimed at enhancing the company's market position and operational efficiency. The release of the CEO Corner segment indicates significant strategic moves that could positively influence the company's trajectory and investor sentiment.

Autonomix Medical, Inc. announced positive results from a post hoc analysis of its pancreatic cancer proof-of-concept study, showing sustained improvements in quality of life for patients. The findings suggest potential benefits of their treatment approach, which may enhance the company's position in the oncology market. Positive subgroup results could significantly impact investor sentiment and the company's future trajectory in the oncology sector.

Autonomix Medical, Inc. (AMIX) has been identified as one of the most active stocks in recent trading sessions, reflecting heightened investor interest and market activity. The company's stock performance has drawn attention, indicating potential shifts in market sentiment and trading volume. Analysts are closely monitoring AMIX for any developments that could influence its future trajectory. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.